The IHCV team provides expertise in a broad range of fields, including the medical, business and legal fields. An advisory panel of medical and business leaders from a wide range of health related disciplines provides support to the management team. This has created a highly effective platform for generating deal flow, assessing the scientific, commercial and investment viability of potential transactions, as well as executing transactions, creating value in portfolio companies, and facilitating exits.

Dr. Hadar Ron
Dr. Hadar RonManaging Partner
Dr. Hadar Ron
Dr. Hadar Ron
Managing Partner
Dr. Hadar Ron is the founding partner of Israel Healthcare Ventures (IHCV). She has an extensive medical, legal and management experience gained in senior positions in the financial, insurance, legal, healthcare sectors.

Dr. Ron serves as an active chairman of the Board of several healthcare companies and is a board member of numerous others. In addition Dr. Ron serves as a member of the Board of Yissum, the technology transfer company of the Hebrew University in Jerusalem and as a member of the advisory Board of the Momentum Fund of Tel Aviv University
Dr. Ron is a physician and attorney by education.

She holds MD and LLB degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University

Eran Perry
Eran PerryPartner
Eran Perry
Eran Perry
Partner
Eran joined IHCV in 2006, and represents the fund in many of its portfolio companies.
Prior to IHCV, Eran was a consultant in McKinsey & Company, serving clients in the Pharmaceuticals, Telecommunications, and Public sectors on strategic and operational matters, in Israel, Europe, and the US. Before that Eran was a member of the Global Marketing group at Novartis Oncology, and a Quantitative Analyst at D.E. Shaw & Co. Before moving to private sector, Eran served in the Israeli Ministry of Justice, at the High Court of Justice Division, and as a Senior Advisor to the Director General of the Ministry.

Eran has an MBA from Columbia University with a major in Finance, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.

Dr. Alona Weiss
Dr. Alona WeissPartner
Dr. Alona Weiss
Dr. Alona Weiss
Partner
Alona joined IHCV in 2005, and is heading the deal flow of the fund. Prior to joining IHCV Alona served as a Senior Licensing Officer at Yeda Research and Development Ltd. – the technology transfer arm of the Weizmann Institute of Science. Before that Alona served as Chief Operation Officer at ProSeed Biotech Services, Inc a Boston based consulting firm and as a Biotechnology Research Manager and ProSeed Capital Holdings CVA., Boston, MA. Prior to that, she was a Research Fellow at Harvard Medical School and at Massachusetts General Hospital.

Alona holds a Ph.D. in Molecular Biology and Biochemistry from the Hebrew University of Jerusalem, a M.Sc. in Life Sciences from the Weizmann Institute of Science, and a B.Sc. from the Hebrew University of Jerusalem (Magna Cum Laude).

Daniella Horev
Daniella HorevAdministrative Manager
Daniella Horev
Daniella Horev
Administrative Manager
Daniella served in several senior administrative positions. Prior to joining IHCV in 2001, Daniella served as an Administrative Manager at TelesensKSCL Israel, a subsidiary of a public German software company. Prior to that she acted as a marketing & sales manager for Medogar Ltd., an Israeli firm focused on importing and distributing pharmaceuticals & medical equipment.

Daniella holds a BA degree from Tel Aviv University.